<DOC>
	<DOCNO>NCT00234637</DOCNO>
	<brief_summary>This prospective , multicenter , open-label study . Following screen baseline assessment , eligible patient switch rivastigmine enter 16 week run-in rivastigmine treatment phase . After completion assessment end run-in phase , patient sufficiently stabilize rivastigmine alone receive add-on memantine rivastigmine treatment ; patient stabilized rivastigmine alone complete discontinue study .</brief_summary>
	<brief_title>Rivastigmine Monotherapy Combination Therapy With Memantine Patients With Moderately Severe Alzheimer 's Disease Who Failed Benefit From Previous Cholinesterase Inhibitor Treatment</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Outpatients probable Alzheimer 's disease accord DSMIV criterion Patients treat donepezil ( 510 mg ) galantamine ( 16 24 mg ) least 6 month Patients , investigator 's clinical judgment , stabilize treatment donepezil galantamine Patients evidence severe unstable physical illness , i.e. , acute severe asthmatic condition , severe unstable cardiovascular disorder , active peptic ulcer disease , hypersensitivity cholinesterase inhibitor memantine , clinically significant laboratory abnormality patient medical condition would prohibit complete clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Alzheimer 's disease ,</keyword>
	<keyword>switch ,</keyword>
	<keyword>rivastigmine ,</keyword>
	<keyword>memantine</keyword>
</DOC>